Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  recombinant interleukin-12
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 34 for your search:
Start Over
Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000064977, NCI-96-C-0113F, NCI-T96-0029N, NCI-MB-386, T96-0029, NCT00019188
Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 9018, UCCRC-9018, UCCRC-8381, NCI-G97-1162, NCT00002952
Phase II Study of Interleukin-12 vs Interferon Alfa-2a in Previously Untreated Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (Summary Last Modified 09/97)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSKCC-97002, ROCHE-BO15469, NCI-G97-1236
Phase II Pilot Study of HER2-Neu Peptide Vaccine in Patients with Recurrent Metastatic Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-97-C-0118, NCI-T97-0009, T97-0009
Phase II Study of Interleukin-12 (IL-12) in Patients With Advanced, Recurrent, or Inoperable Carcinoma of the Cervix
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1E96, E1E96, NCT00003017
Phase II Randomized Study of Interleukin-12 in Patients With Plateau Phase Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-1A96, NCT00003149, E1A96
Phase II Study of Recombinant Human Interleukin-12 in Recurrent, Refractory, and Metastatic Ovarian Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: GOG-170B
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02264, CDR0000066067, NCI-T97-0050, DM-97073, T97-0050, N01CM17003, MDA-DM-97073, NCT00003210
Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066310 (10M-97-3), LAC-USC-10M973, NCI-G98-1432, NCI-T97-0099, T97-0099, NCT00003339
Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 70
Sponsor: NCI
Protocol IDs: NCI-2012-02276, AMC-008, CDR0000066642, NCT00003575
Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000068502, NCI-01-C-0067, NCI-4010, 4010, NCT00020449
Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: 9845, UCCRC-9845, NCI-1192, NCT00015977
Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02381, MDA-ID-00232, N01CM17003, CDR0000068619, NCI-2251, 2251, NCT00016289
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02816, CALGB-500001, CDR0000068990, U10CA031946, NCT00026143
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069220 (10M-01-1), LAC-USC-10M011, LAC-USC-IRB-013030, NCI-5506, 5506, NCT00031733
Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02580, UCCRC-10-324-B, CDR0000696233, 10-324-B, 8445, P30CA014599, N01CM00071, NCT01307618
Phase I Study of Intravenous IL-12 for Advanced Malignancies (Summary Last Modified 03/95)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: PCI-9432, DFCI-94044, NCI-V94-0495
Phase I Study of IL-12 for Advanced Renal Cell Carcinoma (Summary Last Modified 03/97)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSKCC-95008, NCI-V95-0662
Phase I Study of IL-12 Administered with a MART-1 Peptide Vaccine in Patients with Refractory Metastatic Melanoma (Summary Last Modified 11/1999)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-95-C-0143B, NCI-T95-0039N, T95-0039
Interleukin-12 in Treating Patients With Cancer in the Abdomen
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: ID97-027, P30CA016672, MDA-ID-97027, NCI-T97-0034, CDR0000065681, T97-0034, NCT00003046
Interleukin-12 in Treating Patients With Advanced Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000066286, BIH-97-1083, NCI-T97-0053, T97-0053, NCT00003330
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02272, PCI-98-031, PCI-MWH-97-039, NCI-T97-0031, CDR0000066467, T97-0031, NCT00003439
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 13 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01397, OSU-T98-0020, NCI-T98-0020, CDR0000066482, T98-0020, NCT00003451
Start Over